Long-term safety and efficacy of fenofibrate/pravastatin combination therapy in high risk patients with mixed hyperlipidemia not controlled by pravastatin monotherapy

References

• Fruchart J-C, Sacks F, Hermans MP, et al. for the Residual Risk Reduction Initiative (R3i). The residual risk reduction initiative: a call to action to reduce residual vascular risk in patients with dyslipidemia. Am J Cardiol 2008;102(Suppl):1K-34K
   PubMedGoogle Scholar
• Sacks FM, Carey VJ, Fruchart J-C. Combination lipid therapy in type 2 diabetes. N Engl J Med 2010;363:692-4
   PubMed Web of Science ®Google Scholar
• Grundy SM, Cleeman JI, Merz CNB, et al. for the Coordinating Committee of the National Cholesterol Education Program. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines. Circulation 2004;110:227-39
   PubMed Web of Science ®Google Scholar
• The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). ESC/EAS guidelines for the management of dyslipidaemias. Eur Heart J 2011;32:1769-818
   PubMed Web of Science ®Google Scholar
• The ACCORD Study Group. Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med 2010;362:1563-74
   PubMed Web of Science ®Google Scholar
• Farnier M, Ducobu J, Bryniarski L. Efficacy and safety of adding fenofibrate 160 mg in high risk patients with mixed hyperlipidemia not controlled by pravastatin 40 mg monotherapy. Am J Cardiol 2010;106:787-92
   PubMed Web of Science ®Google Scholar
• Miller M, Cannon CP, Murphy SA, et al.; for the PROVE IT-TIMI 22 Investigators. Impact of triglyceride levels beyond low-density lipoprotein cholesterol after acute coronary syndrome in the PROVE IT-TIMI 22 trial. J Am Coll Cardiol 2008;51:724-30
   PubMed Web of Science ®Google Scholar
• Faergeman O, Holme I, Fayyad R, et al. on behalf of the Steering Committees of the IDEAL and TNT trials. Plasma triglycerides and cardiovascular events in the treating to new targets and incremental decrease in end-points through aggressive lipid lowering trials of statins in patients with coronary artery disease. Am J Cardiol 2009;104:459-63
   PubMed Web of Science ®Google Scholar
• Barter P, Gotto AM, LaRosa JC, et al. for the Treating to New Targets Investigators. HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events. N Engl J Med 2007;357:1301-10
   PubMed Web of Science ®Google Scholar
• Arsenault BJ, Barter P, DeMicco DA, et al. Prediction of cardiovascular events in statin-treated stable coronary patients by lipid and nonlipid biomarkers. J Am Coll Cardiol 2011;57:63-9
   PubMed Web of Science ®Google Scholar
• Carey VJ, Bishop L, Laranjo N, et al. Contribution of high plasma triglycerides and low high-density lipoprotein cholesterol to residual risk of coronary heart disease after establishment of low-density lipoprotein cholesterol control. Am J Cardiol 2010;106:757-63
   PubMed Web of Science ®Google Scholar
• Farnier M. Combination therapy with HMG-CoA reductase inhibitor and a fibric acid derivative. A critical review of potential benefits and drawbacks. Am J Cardiovasc Drugs 2003;3:169-78
   PubMedGoogle Scholar
• Ducobu J, Scheen A, Van Gall L, et al. Belgian expert opinion: how to solve the residual risk in atherogenic dyslipidemic patients: place of fibrates. Acta Cardiol 2008;63:235-48
   PubMed Web of Science ®Google Scholar
• Chapman MJ, Ginsberg HN, Amarenco P, et al. for the European Atherosclerosis Society Consensus Panel. Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease: evidence and guidance for management. Eur Heart J 2011;32:1345-61
   PubMed Web of Science ®Google Scholar
• Pan W-J, Gustavson LE, Achari R, et al. Lack of a clinically significant pharmacokinetic interaction between fenofibrate and pravastatin in healthy volunteers. J Clin Pharmacol 2000;40:316-23
   PubMed Web of Science ®Google Scholar
• Gustavson LE, Schweitzer SM, Koehne-Voss S, et al. The effects of multiple doses of fenofibrate on the pharmacokinetics of pravastatin and its 3α-hydroxy isomeric metabolite. J Clin Pharmacol 2005;45:947-53
   PubMed Web of Science ®Google Scholar
• Farnier M, Steinmetz A, Retterstol K, et al. Fixed dose combination fenofibrate/pravastatin 160/40 mg versus simvastatin 20 mg monotherapy in adults with type 2 diabetes and mixed hyperlipidemia uncontrolled with simvastatin 20 mg: a double-blind, randomized comparative study. Clin Ther 2011;33:1-12
   PubMed Web of Science ®Google Scholar
• Athyros VG, Papageorgiou AA, Athyrou VV, et al. Atorvastatin and micronized fenofibrate alone and in combination in type 2 diabetes with combined hyperlipidemia. Diabetes Care 2002;25:1198-202
   PubMed Web of Science ®Google Scholar
• Grundy SM, Vega GL, Yuan Z, et al. Effectiveness and tolerability of simvastatin plus fenofibrate for combined hyperlipidemia (The SAFARI Trial). Am J Cardiol 2005;95:462-8
   PubMed Web of Science ®Google Scholar
• Durrington PN, Tuomilehto J, Hamann A, et al. Rosuvastatin and fenofibrate alone and in combination in type 2 diabetes patients with combined hyperlipidemia. Diab Res Clin Pract 2004;64:137-51
   PubMed Web of Science ®Google Scholar
• Derosa G, Maffioli P, Salvadeo SAT, et al. Fenofibrate, simvastatin and their combination in the management of dyslipidaemia in type 2 diabetic patients. Curr Med Res Opin 2009;25:1973-83
   PubMed Web of Science ®Google Scholar
• Kipnes MS, Roth EM, Rhyne JM, et al. Year two assessment of fenofibric acid and moderate-dose statin combination. A phase 3, open-label, extension study. Clin Drug Investig 2010;30:51-61
   PubMed Web of Science ®Google Scholar
• Bays HE, Jones PH, Mohiuddin SM, et al. Long-term safety and efficacy of fenofibric acid in combination with statin therapy for the treatment of patients with mixed dyslipidemia. J Clin Lipidol 2008;2:426-35
   PubMed Web of Science ®Google Scholar
• Enger C, Gately R, Ming EE, et al. Pharmacoepidemiology safety study of fibrate and statin concomitant therapy. Am J Cardiol 2010;106:1594-601
   PubMed Web of Science ®Google Scholar
• Davidson MH, Armani A, McKenney JM, et al. Safety considerations with fibrate therapy. Am J Cardiol 2007;99(Suppl):3C-18C
   PubMed Web of Science ®Google Scholar
• Corsini A, Bellosta S, Davidson MH. Pharmacokinetic interactions between statins and fibrates. Am J Cardiol 2005;96(Suppl):44K-49K
   PubMedGoogle Scholar
• Jacobson TA. Myopathy with statin–fibrate combination therapy: clinical considerations. Nat Rev Endocrinol 2009;5:507-18
   PubMed Web of Science ®Google Scholar
• McKeage K, Keating GM. Fenofibrate. A review of its use in dyslipidaemia. Drugs 2011;71:1917-46
   Google Scholar